SIRPB1: A Potential Drug Target and Biomarker (G10326)

Target Name: SIRPB1

NCBI ID: G10326

SIRPB1

SIRPB1: A Potential Drug Target and Biomarker

SIRPB1 (CD172b), a type of carbohydrate-binding protein (CBP), has been identified as a potential drug target and biomarker for various diseases, including cancer, diabetes, and neurodegenerative disorders. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.

SIRPB1 is a 21-kDa protein that is expressed in various tissues and cells in the body. It is composed of a N-terminal cytoplasmic domain, a transmembrane region, and an C-terminal cytoplasmic domain. The cytoplasmic domain is the region of the protein that interacts with extracellular matrix (ECM) components, such as extracellular matrix (CE), which is a complex mixture of cytoskeletal components and extracellular matrix proteins that provides structural support and maintain cell shape, as well as participating in various signaling pathways ( 1).

SIRPB1 functions as a carbohydrate-binding protein by its ability to recognize and interact with ECM components. It has been shown to interact with a variety of ECM components, including glycophorin A (GPI-A), which is a type of ECM protein that is expressed in many cell types and plays a role in cell adhesion, migration, and signaling. In addition, SIRPB1 has been shown to interact with hyaluronic acid, a type of ECM component that is involved in tissue hydration and repair.

The unique carbohydrate-binding properties of SIRPB1 have led to its potential as a drug target. One of the main advantages of SIRPB1 as a drug target is its ability to interact with a variety of ECM components, which can provide a wide range of potential drug targets. For example, SIRPB1 has been shown to interact with GPI-A, which can be targeted with small molecules, such as those used to treat hypertension or diabetes. Additionally, SIRPB1 can interact with hyaluronic acid, which can be targeted with anti- inflammatory drugs.

In addition to its potential as a drug target, SIRPB1 has also been identified as a potential biomarker for various diseases. Its carbohydrate-binding properties make it an attractive target for diagnostic tests that detect carbohydrates in biological samples, such as urine or tissue samples. For example, SIRPB1 has been shown to be expressed in various types of cancer, including breast, ovarian, and prostate cancer, and has been used as a biomarker for these cancers.

In conclusion, SIRPB1 is a unique protein with carbohydrate-binding properties that has the potential to be a drug target or biomarker for various diseases. Its interaction with ECM components makes it an attractive target for small molecules, and its carbohydrate-binding properties make it an attractive target for diagnostic tests that detect carbohydrates in biological samples. Further research is needed to fully understand the potential of SIRPB1 as a drug target and biomarker.

Protein Name: Signal Regulatory Protein Beta 1

Functions: Immunoglobulin-like cell surface receptor involved in the negative regulation of receptor tyrosine kinase-coupled signaling processes. Participates also in the recruitment of tyrosine kinase SYK. Triggers activation of myeloid cells when associated with TYROBP (PubMed:10604985)

The "SIRPB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SIRPB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets